Compare IDEXX Laboratories, Inc. (IDXX) vs NIO Inc. (NIO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs NIO Inc. — how do they compare? IDEXX Laboratories, Inc. trades at $569.65 (market cap $46.22B), while NIO Inc. trades at $4.56 (market cap $11.59B). The key difference: IDEXX Laboratories, Inc. is far larger — about 4× NIO Inc.'s market cap, and IDEXX Laboratories, Inc. is trading nearer its 52-week high, NIO Inc. nearer its low. Which is the better fit depends on your goals.
| IDXX | NIO | |
|---|---|---|
Market Cap | $46.22B | $11.59B |
Sector | Health | Consumer Cyclical |
52-Week High | $766.68 | $7.89 |
52-Week Low | $526.44 | $4.44 |
Enterprise Value | $47.12B | $10.82B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $570.58, down 4.23% over 24 hours, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $4.27 surpassing the $3.94 expectation. Revenue growth remains robust, supported by a 74.21% ROE and expanding diagnostic offerings. Recent news highlights product expansion, including a dual-species cardiac test, reinforcing its market leadership in veterinary diagnostics.
The outlook is positive, driven by durable competitive advantages and international growth potential. However, elevated valuation multiples and competitive pressures pose risks. Analyst consensus is bullish with a $683.33 price target, suggesting significant upside from current levels, though investors should monitor execution on guidance and macroeconomic headwinds.
NIO's stock trades at $4.555, down 5.5% in the last session amid a bearish technical signal and negative cash flow trends. The company shows revenue growth with 2025 sales reaching $87.49 billion, but remains unprofitable with a net loss of $15.57 billion. Recent news highlights delivery growth and policy support for EVs in China, yet investor sentiment is mixed due to competitive pressures and high cash burn.
The outlook is cautious; while analyst consensus leans bullish with 54% buy ratings, fundamental weaknesses in profitability and negative equity pose significant risks. Upside depends on sustained revenue expansion and cost control, but volatility from market sentiment and execution challenges warrants careful monitoring for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About NIO Inc.
NIO Inc. manufactures and sells automobiles. The Company offers electric vehicles and parts, as well as provides battery charging services. NIO serves customers worldwide.
Read more on NIO →
